KR20240149982A - 항-pd-1 항체를 사용하여 종양을 치료하는 방법 - Google Patents

항-pd-1 항체를 사용하여 종양을 치료하는 방법 Download PDF

Info

Publication number
KR20240149982A
KR20240149982A KR1020247032911A KR20247032911A KR20240149982A KR 20240149982 A KR20240149982 A KR 20240149982A KR 1020247032911 A KR1020247032911 A KR 1020247032911A KR 20247032911 A KR20247032911 A KR 20247032911A KR 20240149982 A KR20240149982 A KR 20240149982A
Authority
KR
South Korea
Prior art keywords
tumor
antibody
subject
stk11
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032911A
Other languages
English (en)
Korean (ko)
Inventor
로빈 에드워즈
윌리엄 제이. 기스
다니엘 엠. 그리나월트
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20240149982A publication Critical patent/KR20240149982A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247032911A 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법 Pending KR20240149982A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762513831P 2017-06-01 2017-06-01
US62/513,831 2017-06-01
PCT/US2018/035670 WO2018223040A1 (en) 2017-06-01 2018-06-01 Methods of treating a tumor using an anti-pd-1 antibody
KR1020197038639A KR102714702B1 (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038639A Division KR102714702B1 (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20240149982A true KR20240149982A (ko) 2024-10-15

Family

ID=62685228

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247032911A Pending KR20240149982A (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법
KR1020197038639A Active KR102714702B1 (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197038639A Active KR102714702B1 (ko) 2017-06-01 2018-06-01 항-pd-1 항체를 사용하여 종양을 치료하는 방법

Country Status (6)

Country Link
US (3) US11566073B2 (https=)
EP (1) EP3630840A1 (https=)
JP (3) JP7780857B2 (https=)
KR (2) KR20240149982A (https=)
CN (2) CN117462668A (https=)
WO (1) WO2018223040A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
KR20240149982A (ko) 2017-06-01 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 종양을 치료하는 방법
SG11202007590TA (en) * 2018-02-13 2020-09-29 Merck Sharp & Dohme Methods for treating cancer with anti-pd-1 antibodies
CN111821434A (zh) * 2019-04-17 2020-10-27 上海君实生物医药科技股份有限公司 抗pd-1抗体在制备治疗实体瘤的药物中的用途
JP2022514952A (ja) * 2018-12-19 2022-02-16 ストラータ オンコロジー， インコーポレイテッド チェックポイント阻害薬応答性がんを有する対象を検出及び処置する方法
CN114269376A (zh) * 2019-05-03 2022-04-01 豪夫迈·罗氏有限公司 用抗pd-l1抗体治疗癌症的方法
US12275986B2 (en) * 2020-01-06 2025-04-15 Duke University Biomarkers associated with checkpoint immune therapy and methods of using same
CN110923329B (zh) * 2020-02-06 2020-05-12 至本医疗科技（上海）有限公司 Fgfr4点突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
CN111440822A (zh) * 2020-04-16 2020-07-24 苏州大学附属第二医院 一种突变lats1质粒的构建与应用
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
CN112961920A (zh) * 2021-03-24 2021-06-15 臻和(北京)生物科技有限公司 一种预测肝胆肿瘤患者免疫检查点抑制剂联合靶向治疗疗效的方法及产品
JP7806990B2 (ja) * 2021-08-10 2026-01-27 国立大学法人 新潟大学 内胚葉嚢胞の悪性化に関連する遺伝子の検出方法
CN113943806A (zh) * 2021-11-04 2022-01-18 至本医疗科技（上海）有限公司 预测肺腺癌患者对免疫疗法敏感性的生物标志物、应用和装置
US20250349434A1 (en) * 2022-04-26 2025-11-13 Hoffmann-La Roche Inc. Methods and systems for predicting cancer therapy response
CN114931637B (zh) * 2022-06-27 2025-02-18 中山大学中山眼科中心 Pdl1抗体在角膜新生血管疾病中的应用
CN115825441B (zh) * 2023-01-30 2023-05-26 上海秤信生物科技有限公司 预测肺癌三期患者的免疫新辅助疗效的自身抗体标志物
WO2025085707A1 (en) * 2023-10-19 2025-04-24 Tesaro, Inc. Methods of treating cancer with anti-pd-1 agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
SMT202100065T1 (it) 2013-05-02 2021-03-15 Anaptysbio Inc Anticorpi diretti contro la proteina della morte programmata (pd-1)
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
EP3134546A4 (en) * 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
DK3237446T3 (en) 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
US20180155429A1 (en) * 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
HUE068868T2 (hu) 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
EP4458417A3 (en) 2015-08-11 2025-02-19 Wuxi Biologics Ireland Limited Novel anti-pd-1 antibodies
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
AU2016317915B2 (en) 2015-09-01 2021-02-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them
US11814679B2 (en) 2016-01-11 2023-11-14 Eli Lilly And Company Interleukin-10 production of antigen-specific CD8+ T cells and methods of use of same
CN108029076B (zh) 2016-02-02 2020-03-10 华为技术有限公司 确定发射功率的方法、用户设备和基站
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN109476753A (zh) 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗肿瘤的方法的抗-pd-1抗体
KR20240149982A (ko) 2017-06-01 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체를 사용하여 종양을 치료하는 방법
CN113249483B (zh) * 2021-06-10 2021-10-08 北京泛生子基因科技有限公司 一种检测肿瘤突变负荷的基因组合、系统及应用

Also Published As

Publication number Publication date
KR102714702B1 (ko) 2024-10-10
US12227576B2 (en) 2025-02-18
JP2020522508A (ja) 2020-07-30
CN110678483A (zh) 2020-01-10
US20200109204A1 (en) 2020-04-09
US20230279114A1 (en) 2023-09-07
US20250145713A1 (en) 2025-05-08
JP2023159179A (ja) 2023-10-31
CN110678483B (zh) 2023-09-22
EP3630840A1 (en) 2020-04-08
JP7780857B2 (ja) 2025-12-05
JP2026053613A (ja) 2026-03-25
WO2018223040A1 (en) 2018-12-06
KR20200014363A (ko) 2020-02-10
CN117462668A (zh) 2024-01-30
US11566073B2 (en) 2023-01-31

Similar Documents

Publication Publication Date Title
KR102714702B1 (ko) 항-pd-1 항체를 사용하여 종양을 치료하는 방법
US12466888B2 (en) Methods of treating tumor
KR102775647B1 (ko) 종양을 치료하는 방법
US20240190963A1 (en) Methods of treating tumor
US12479917B2 (en) Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody
US20260042840A1 (en) Methods of treating tumor

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20241002

Application number text: 1020197038639

Filing date: 20191227

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241101

Comment text: Request for Examination of Application